Regeneron Reaches New 52-Week High (REGN)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- Regeneron Pharmaceuticals (Nasdaq: REGN) hit a new 52-week high Thursday as it is currently trading at $151.33, above its previous 52-week high of $150.82 with 75,564 shares traded as of 9:40 a.m. ET. Average volume has been 814,500 shares over the past 30 days.

Regeneron has a market cap of $14.11 billion and is part of the health care sector and drugs industry. Shares are up 170.9% year to date as of the close of trading on Wednesday.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States.

TheStreet Ratings rates Regeneron as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, compelling growth in net income, impressive record of earnings per share growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Regeneron Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)